alexa Management Of Late-stage Neovascular Glaucoma
ISSN: 2155-9570

Journal of Clinical & Experimental Ophthalmology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

World Ophthalmology Conference
November 24-25, 2016 Melbourne, Australia

Melissa Marselina and Andika Prahasta Gandasubrata
Padjadjaran University Cicendo National Eye Hospital, Indonesia
ScientificTracks Abstracts: J Clin Exp Ophthalmol
DOI: 10.4172/2155-9570.C1.051
Introduction: Neovascular glaucoma (NVG) is a common, severe type of secondary glaucoma caused by retinal ischemia or ocular inflammation. The treatment of NVG varies depending on the stage of the disease. Intravitreal bevacizumab (IVB) can be considered in NVG. Purpose: To report one case of late-stage NVG and its management. Case report: A 31-year-old woman has been consulted from vitreoretinal subdivision to glaucoma subdivision with chief complain of pain in the left eye (LE) since 1 week before admission. The patient had been diagnosed with bilateral proliferative diabetic retinopathy (PDR), attached retina of the right eye (RE), tractional retinal detachment of the LE, and uncontrolled diabetes mellitus with history of five retinal surgeries of the RE and series of bilateral panretinal photocoagulation (PRP). During one year follow-up at Vitreoretinal Clinic, there were no abnormalities found in the anterior segment of both eyes but a progressive decrease of vision was found. Upon first examination at Glaucoma Clinic, the visual acuity was hand movement bilaterally with IOP of 18 mmHg (RE) and 30 mmHg (LE). Ciliary injection, microcystic edema, shallow AC, mid-dilated pupil, posterior synechiae, and neovascularization of the iris (NVI) on the LE were found. Patient was diagnosed with additional latestage NVG and was successfully managed by laser trans-scleral cyclophotocoagulation (TSCPC) over IVB. Conclusion: Intravitreal bevacizumab is effectively stabilized NVI activity and controlled IOP in patients with NVI alone and early-stage NVG without angle closure but cannot control IOP in advanced NVG. Laser TSCPC is effective in lowering IOP in NVG.

Melissa Marselina has completed her Medical Doctor degree from Padjadjaran University. She is now in her second year of Ophthalmology Residency at Cicendo National Eye Hospital. She has published her first e-poster internationally at 7th International Conference on Ocular Infections 2015 in Barcelona and was once a Study Coordinator for research program at Vitreoretina sub-division, Cicendo National Eye Hospital.

image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version